Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus

Publication information:

Mineo, Marco, Shawn Lyons, Mykola Zdioruk, Niklas Spreckelsen, Ruben Ferrer-Luna, Hirotaka Ito, Quazim Alayo, Prakash Kharel, Alexandra Giantini Larsen, William Fan, Sophia Auduong, Korneel Grauwet, Carmela Passaro, Jasneet Khalsa, Khalid Shah, David Reardon, Keith Ligon, Rameen Beroukhim, Hiroshi Nakashima, Pavel Ivanov, Paul Anderson, Sean Lawler, and Antonio Chiocca. [2020] 2020. “Tumor Interferon Signaling Is Regulated by a LncRNA INCR1 Transcribed from the PD-L1 Locus”. Mol Cell 78(6):1207-1223.e8. doi:10.1016/j.molcel.2020.05.015.

Abstract

Tumor interferon (IFN) signaling promotes PD-L1 expression to suppress T cell-mediated immunosurveillance. We identify the IFN-stimulated non-coding RNA 1 (INCR1) as a long noncoding RNA (lncRNA) transcribed from the PD-L1 locus and show that INCR1 controls IFNγ signaling in multiple tumor types. Silencing INCR1 decreases the expression of PD-L1, JAK2, and several other IFNγ-stimulated genes. INCR1 knockdown sensitizes tumor cells to cytotoxic T cell-mediated killing, improving CAR T cell therapy. We discover that PD-L1 and JAK2 transcripts are negatively regulated by binding to HNRNPH1, a nuclear ribonucleoprotein. The primary transcript of INCR1 binds HNRNPH1 to block its inhibitory effects on the neighboring genes PD-L1 and JAK2, enabling their expression. These findings introduce a mechanism of tumor IFNγ signaling regulation mediated by the lncRNA INCR1 and suggest a therapeutic target for cancer immunotherapy.